Pacira BioSciences will divest its iovera business to Zimmer Biomet for up to $140 million. The deal is a positive capital-reallocation step for PCRX, though the headline does not specify timing or whether the full amount is expected to be realized.
Pacira BioSciences will divest its iovera business to Zimmer Biomet for up to $140 million. The deal is a positive capital-reallocation step for PCRX, though the headline does not specify timing or whether the full amount is expected to be realized.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
